Category Archives: Artificial Intelligence

Latest iteration of patent pending platform enables life sciences and pharmaceutical companies to access insights from billions of proprietary data points

London, U.K. August 9, 2023. Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today launched its new enhanced search platform leveraging generative artificial intelligence (GenAI). GenAI has the potential to yield efficiencies across the entire Life Sciences & Healthcare value chain. The new Clarivate offering enables drug discovery, preclinical, clinical, regulatory affairs and portfolio strategy teams to interact with multiple complex datasets using natural language to obtain immediate and in-depth insights.

Rapid, accurate insights are challenged by a typical paradigm of disparate, siloed data sources. Many standard databases and companies have focused use cases and the ability to track scientific innovation from start to finish is complex, costly, and inefficient. The new Clarivate enhanced search platform addresses these obstacles by pairing billions of proprietary data points and over 100 years of deep industry and domain expertise with GenAI capabilities. By integrating vast content sets and analytics from solutions, including Cortellis Competitive Intelligence, Disease Landscape & Forecast and Drug Timelines and Success Rates (DTSR) into the new interactive platform, users can access harmonized data featuring precise, concise and immediate answers to the life science industrys most urgent questions.

Researchers can access and interrogate epidemiologic, scientific, clinical, commercial and research data within one platform to overcome barriers to enabling evidence-based decisions and complex analyses. Derived from advanced GenAI and data science techniques that algorithmically process high-value curated content, users can identify companies developing breakthrough therapies, anticipate medical advancements and understand market dynamics, essential for the advancement of bringing new therapies to market. Additional features and functionalities include among others:

The beta version of the enhanced search platform has been launched with select customers to optimize the platform for use by broader audiences by discovering new use cases, exploring UI / UX capabilities, obtaining and incorporating feedback and previewing new features and functionality. Commercialization is anticipated later this year, with plans to extend the knowledge base by integrating additional datasets from solutions, including: Cortellis Clinical Trials Intelligence, Cortellis Deals Intelligence, OFF-X Safety Intelligence, Cortellis Drug Discovery Intelligence, Cortellis Regulatory Intelligence and others. Clarivate will continue to evolve the platform with technical enhancements, heightened search capabilities, data mapping and AI model updates in the near term.

Henry Levy, President, Life Sciences and Healthcare, Clarivate, said: There is a growing need for data to support complex analyses and evidence-based decisions in the life sciences. As an early adopter of AI technology, Clarivate utilizes billions of proprietary best-in-class data assets to enable researchers to optimize treatment development from early-stage drug discovery through commercialization. The new Clarivate GenAI enhanced search platform utilizes human expertise, billions of proprietary best-in-class expertly curated and interconnected data assets, and advanced AI models to enhance decision-making, advance research, and boost clinical and commercial success across the entire drug, device and medical technology lifecycle.

As a provider of best-in-class data integration/deidentified patient solutions and a premier end-to-end research intelligence solution, Clarivate is committed to comprehensively supporting customers across the entire drug, device or diagnostic product lifecycle to help them advance human health. Our continuing investment in artificial intelligence (AI) and machine learning (ML) supports the industrys ever-growing need to engage patients, physicians and payers in new ways, navigate barriers to access and adherence, and address patient unmet needs.

To learn more about the Clarivate enhanced search platform, contact: LSHGenAI@clarivate.com.

# # #

About Clarivate

Clarivate is a leading global information services provider. We connect people and organizations to intelligence they can trust to transform their perspective, their work and our world. Our subscription and technology-based solutions are coupled with deep domain expertise and cover the areas of Academia & Government, Life Sciences & Healthcare and Intellectual Property. For more information, please visit http://www.clarivate.com.

Media contact:

Catherine Daniel Director External Communications, Life Sciences & Healthcare newsroom@clarivate.com

See the original post:

Clarivate Launches Enhanced Search Powered by Generative ... - Clarivate

The University of North Florida (UNF) is offering a six-month bootcamp to teach students the skills needed to master Artificial Intelligence (AI) and Machine Learning or DevOps. With both skill sets in high demand, these bootcamps provide a great opportunity for those interested in learning about this emerging technology.

Partnering with Fullstack Academy, UNF has designed these bootcamp programs to be completed online over a span of 26 weeks. Students will learn the concepts and theoretical information about AI and machine learning, and then have the opportunity to apply those concepts through hands-on training.

The job market for AI and machine learning professionals in the United States is projected to grow by 22% by 2030, according to the U.S. Bureau of Labor Statistics. Additionally, the AI industry has the potential to contribute $15.7 trillion to the global economy by 2035, as reported by PwC. With such promising growth and opportunities, these bootcamps offer a pathway to a high-paying skillset.

In Jacksonville alone, there are currently 190 job openings for Artificial Intelligence Engineer positions, many of which offer remote or hybrid work options, with entry-level positions paying up to $178,000 annually.

The AI and Machine Learning Bootcamp will start on September 11, and the DevOps program will start on August 28. The application deadlines are September 5 and August 22, respectively.

One of the unique aspects of these bootcamp programs is the availability of career success coaches who will assist students with developing their resume, creating LinkedIn profiles, and attending networking events with potential employers. Upon completion of the programs, students will receive a UNF digital credential that can be shared with employers to showcase their certified skills.

The cost of the bootcamp programs is $13,000, but scholarships, loans, and payment plans are available for those in need of financial assistance.

Original post:

University of North Florida Launches Artificial Intelligence & Machine ... - Fagen wasanni

A new state office of AI Safety and Regulation could take a risk-based approach to regulating various AI products.

Not a day passes without a major news headline on the great strides being made on artificial intelligence and warnings from industry insiders, academics and activists about the potentially very serious risks from AI.

A 2023survey of AI expertsfound that 36% fear that AI development may result in a nuclear-level catastrophe. Almost 28,000 people have signed on to anopen letterwritten by the Future of Life Institute, including Steve Wozniak, Elon Musk, the CEOs of several AI companies and many other prominent technologists, asking for a six-month pause or a moratorium on new advanced AI development.

As a public policy lawyer and also a researcher in consciousness (I have a part-time position at UC Santa Barbaras META Lab I share these strong concerns about the rapid development of AI, and I am a co-signer of the Future of Life open letter.

Why are we all so concerned? In short: AI development is going way too fast and its not being regulated.

The key issue is the profoundly rapid improvement in the new crop of advanced chatbots, or what are technically called large language models such as ChatGPT, Bard, Claude 2, and many others coming down the pike.

The pace of improvement in these AIs is truly impressive. This rapidaccelerationpromises to soon result in artificial general intelligence, which is defined as AI that is as good or better on almost anything a human can do.

When AGI arrives, possibly in the near future but possibly in a decade or more, AI will be able toimproveitself with no human intervention. It will do this in the same way that, for example, GooglesAlphaZeroAI learned in 2017 how to play chess better than even the very best human or other AI chess players in just nine hours from when it was first turned on. It achieved this feat by playing itself millions of times over.

In testing GPT-4, it performed better than90%of human test takers on the Uniform Bar Exam, a standardized test used to certify lawyers for practice in many states. That figure was up from just 10% in the previous GPT-3.5 version, which was trained on a smaller data set. They found similar improvements in dozens of other standardized tests.

Most of these tests are tests of reasoning, not of regurgitated knowledge. Reasoning is perhaps the hallmark of general intelligence so even todays AIs are showing significant signs of general intelligence.

This pace of change is why AI researcher Geoffrey Hinton, formerly with Google for a number of years,toldtheNew York Times: Look at how it was five years ago and how it is now. Take the difference and propagate it forwards. Thats scary.

In a mid-May Senate hearing on the potential of AI, Sam Altman, the head of OpenAI called regulation crucial. But Congress has done almost nothing on AI since then and the White House recently issued a letter applauding a purely voluntary approach adopted by the major AI development companies like Google and OpenAI.

A voluntary approach on regulating AI safety is like asking oil companies to voluntarily ensure their products keep us safe from climate change.

With the AI explosion underway now, and with artificial general intelligence perhaps very close, we may have just onechanceto get it right in terms of regulating AI to ensure its safe.

Im working with Hawaii state legislators to create a new Office of AI Safety and Regulation because the threat is so immediate that it requires significant and rapid action. Congress is working on AI safety issues but it seems that Congress is simply incapable of acting rapidly enough given the scale of this threat.

The new office would follow the precautionary principle in placing the burden on AI developers to demonstrate that their products are safe for Hawaii before they are allowed to be used in Hawaii. The current approach by regulators is to allow AI companies to simply release their products to the public, where theyre being adopted at record speed, with literally no proof of safety.

We cant afford to wait for Congress to act.

The new Hawaii office of AI Safety and Regulation would then take a risk-based approach to regulating various AI products. This means that the office staff, with public input, would assess the potential dangers of each AI product type and would impose regulations based on the potential risk. So less risky products would be subject to lighter regulation and more risky AI products would face more burdensome regulation.

My hope is that this approach will help to keep Hawaii safe from the more extreme dangers posed by AI which another recent open letter, signed by hundreds of AI industry leaders and academics, warned should be considered as dangerous as nuclear war or pandemics.

Hawaii can and should lead the way on a state-level approach to regulating these dangers. We cant afford to wait for Congress to act and it is all but certain that anything Congress adopts will be far too little and too late.

Sign Up

Sorry. That's an invalid e-mail.

Thanks! We'll send you a confirmation e-mail shortly.

Read more:

Why Hawaii Should Take The Lead On Regulating Artificial ... - Honolulu Civil Beat

PEWAUKEE, Wis. (Thursday, Aug 10, 2023) Starting in the fall semester, Waukesha County Technical College will add three new information technology certificates two in artificial intelligence and one in data analytics -- and build upon the robust IT offerings available within the School of Business.

These include:

These certificates really complement our existing Data and Analytics Specialist program, said Alli Jerger, associate dean of Information Technology. Students in the Data and Analytics program, or those who may be pursuing certificates within that area, will find that they can rapidly move toward an AI certificate.

The College began its initial research for AI programming more than two years ago, Jerger said. With input from business and industry representatives who would need employees with these skillsets in the near future, WCTC began developing the AI certificates in fall of 2022 with the goal of launching them in August 2023.

Because AI is an emerging field, business and industry leaders have also been working to determine how their companies can leverage AI and ensure employment opportunities for graduates, Jerger said.

Employers told us that they will be looking for people who can help identify the right data to feed into AI tools, and who can help that data and the results that come from AI tell a story, she said. These new certificates are just the beginning of what WCTC plans to offer for AI programming, Jerger said. The College is creating a full Associate of Applied Science degree in AI, which will be launched in fall of 2024 (pending approval); credits from the AI certificates have been designed to transfer into that degree program.

Read more from the original source:

WCTC To Offer New Certificates In Artificial Intelligence And Data ... - Patch

Notably, the number of artificial intelligence-related patent applications in the pharmaceutical industry was 70 in Q2 2023, versus 46 in the prior quarter.

Analysis of patenting activity by companies shows that Koninklijke Philips filed the most artificial intelligence patents within the pharmaceutical industry in Q2 2023. The company filed 13 artificial intelligence-related patents in the quarter. It was followed by Japanese Foundation for Cancer Research with 2 artificial intelligence patent filings, Syqe Medical (2 filings), and Hangzhou DAC Biotech (2 filings) in Q2 2023.

The largest share of artificial intelligence related patent filings in the pharmaceutical industry in Q2 2023 was in the US with 50%, followed by China (23%) and Japan (3%). The share represented by the US was 15% lower than the 65% share it accounted for in Q1 2023.

To further understand GlobalData's analysis on Artificial Intelligence (AI) in Drug Discovery Market - Thematic Research buy the report here.

This content was updated on 2 August 2023

Get industry leading news, data and analysis delivered to your inbox

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalDatas Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the worlds largest industries.

See original here:

Artificial Intelligence related patent filings increased in the ... - Pharmaceutical Technology